ALK-Abelló (ALK) CMD 2024 summary

Strategic direction and future plans

• Launched the Allergy+ strategy, focusing on market expansion, innovation, operational optimization, and a global culture, aiming to double annual patients treated from 2.4 million to 5 million by 2030.

• Growth will be driven by expanding pediatric and geographic coverage, especially in Europe, Japan, China, and North America, and by entering food allergy and anaphylaxis markets.

• Sustained investment in R&D, digitalization, and partnerships to build a balanced pipeline and enter adjacent therapy areas.

• Operational excellence through simplification, digital infrastructure, and increased tablet production capacity to 800 million by 2030.

• Commitment to sustainability, upskilling, diversity, and reducing CO2 emissions by 42% by 2030, aligned with the Paris Agreement.

Financial guidance and performance

• Targets average annual sales growth above 10% and an EBIT margin of 25% through 2028, with 2024 EBIT margin guidance at 17%-19%.

• Revenue growth aspiration of 10–13% in 2024, with EBIT margin expected to reach ~25% in 2025–2028.

• Plans to increase R&D spending to up to 15% of revenue, focusing on pipeline expansion and external innovation.

• Maintains a conservative capital structure, prioritizing organic growth, business development, and shareholder returns, with financial gearing capped at 2x NIBD/EBITDA.

• Free cash flow and profitability to increase, supported by cost savings and operational optimizations.

Business development and pipeline

• Pipeline expansion is a priority, with a focus on both internal R&D and external partnerships to address mid-term gaps and diversify into adjacent allergic diseases.

• Accelerating development of a peanut SLIT-tablet (Phase I/II), with launches in pediatric, anaphylaxis, and food allergy segments planned and regulatory submissions ongoing.

• R&D pipeline broadened to include new mechanisms of action, digital tools, and AI for drug development and evidence generation.

• Strategic partnerships in Japan, China, and with academic institutions to accelerate innovation and market access.

• Collaboration with Windgap Medical for autoinjectors will be terminated, with no financial impact.